Introduction
Aortic valve stenosis (AVS) is one of the most frequent structural pathologies of the heart, particularly in older patients [1] . The development of symptoms associated to the disease is an indicator of poor prognosis. It increases the two years mortality risk in more than half of the affected individuals [2] . Open-heart conventional surgery decreases symptoms and improves survival [3] . However, it cannot be performed in about a third of patients due to their poor medical condition [4] . Medical management alone is the only remaining option for this group of patients. Transcatheter Aortic Valve Implantation (TAVI) is a minimally-invasive technique that offers a therapeutic alternative superior to medical management (PARTNER study, US) in inoperable patients with severe AVS.
. Over the 3 year period of analysis, 2.12 life years per patient were achieved with TA TAVI, 2.31 with TF TAVI and 1.51 with MEDICAL management, representing 1.24, 1.38 and 0.74 QALYs, respectively (Table 4) .
While the estimated cost per patient treated with TAVI remained very much the same over the three years of analysis, the cost per patient managed with MEDICAL treatment tended to increase over time, indicating that TAVI might become a more cost-effective alternative over the years.
The scatter plot diagram (Figure 2) shows that TAVI provides better clinical A deterministic longitudinal cohort economic model was developed (Figure 1) to predict the clinical and economic outcomes of symptomatic AVS patients treated with either transapical (TA) or transfemoral (TF) TAVI, or with medical management
Methods

Objective
To estimate the cost-effectiveness of TAVI Edwards SAPIEN, delivered through the transapical (TA-TAVI) or transfemoral (TF-TAVI) approach compared to conservative medical management alone in high risk or inoperable patients with symptomatic AVS in Spain.
The cost/QALY gained was €28,003 for TA TAVI and €19,499 for TF TAVI, both ratios remaining well below the accepted threshold for Spain [8] .
Results
Ferreira-González I 1 , Serra V 1 , Abdul O 1 , Lizan L 2 , Paz S 2 , Banz K 3 , Sureda C 1 , Igual A 1 , García Del Blanco B 1 , Ángel J 1 , García-Dorado D 1 , Tornos P 1 . The scatter plot diagram (Figure 2) shows that TAVI provides better clinical results, but at a higher cost than MEDICAL management only.
. Considering a maximum acceptable ceiling ratio of € 30,000, TF TAVI had a 100% probability of being cost -effective while the chances for TF TAVI for being costeffective, was of 60%. management alone (Figure 3) .
with either transapical (TA) or transfemoral (TF) TAVI, or with medical management alone (MEDICAL) over three years. The perspective adopted was that of the National Health System in Spain. Only direct costs were taking into account. Benefits and costs were discounted with 3% per year.
Clinical input data for TAVI was derived from the real-world SOURCE (SAPIEN Aortic Bioprosthesis European Outcomes) registry [5], and for MEDICAL it was gathered from a registry of 60 Spanish AVS patients followed up during 336 days in a tertiary hospital (Table 1) , and from the literature. They included early perioperative (30 days) and late complications (6, 12, 24, 36 months). In Table 2 , the corresponding incidence figures for early complications for TAVI and for MEDICAL patients used for the base case scenario are summarized.
Estimates on the use of resources considered diagnostic and follow up visits, hospital admissions, length of hospital stay, domiciliary hospitalization and home care. Each different clinical outcome and resource used was assigned a specific cost value. Table 3 shows the corresponding of cost value for the clinical event and the medical resource utilization incorporated into the model.
Health utility estimates were based on published data [6, 7] . Missing information 
Conclusions
References ►For high-risk inoperable patients with symptomatic AVS, TAVI resulted to be cost-effective compared to MEDICAL treatment alone in Spain.
►Patients survival was longer, and more years of life with better quality were gained with TAVI than with medical treatment alone.
►The initial high acquisition costs of the device was offset over time by the cumulative savings derived from preventing hospital readmissions for cardiac reasons.
►These findings, however, have to be interpreted in the context of the model limitations inherent to its nature and to the diversity of the sources of information used. These limitations are similar to the identified by other authors [6] .
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